Escitalopram [Inn]

• Antidepressive Agents, Second-Generation
• Serotonin Uptake Inhibitors
• ATC:N06AB10

• Escitalopram Oxalate
• Escitalopram [Inn]
• Lexapro

• No information avaliable

C₂₀H₂₁FN₂O

http://www.rxlist.com/cgi/generic/lexapro.htm

Escitalopram_[Inn] FDA

No information avaliable

324.392 g/mol

No information avaliable

No information avaliable

Solid

4.222

Tablet

For the treatment of major depressive disorder and Generalized Anxiety Disorder (GAD).

Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT_1A, 5HT_1B, 5HT₂), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase.

The absolute bioavailability of citalopram is about 80% relative to an intravenous dose

Signs of overdose include convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation).

Humans and other mammals